The level of endogenous testosterone and its correlation with lipid profile in men older than 40 years with acute myocardial infarction

Branko Barać; Sanja Stanković; Milika Ašanin; Zorana Vasiljević-Pokrajčić; Svetlana Vujović

doi:10.2298/VSP180519135B

Branko Barać Institute for Rheumatology, Belgrade, Serbia
Sanja Stanković Clinical Centre of Serbia, Center for Medical Biochemistry, Belgrade, Serbia
Milika Ašanin Clinical Centre of Serbia, Clinic for Cardiology, Belgrade, Serbia
Zorana Vasiljević-Pokrajčić Clinical Centre of Serbia, Clinic for Cardiology, Belgrade, Serbia
Svetlana Vujović University of Belgrade, Faculty of Medicine, Belgrade, Serbia

DOI: https://doi.org/10.2298/VSP180519135B

Keywords: lipids, lipoproteins, myocardial infarction, testosterone

Abstract

Background/Aim. The influence of lipid profile on acute myocardial infarct (AMI) is well known. On the other hand, the role of testosterone (T), as one of the possible predictive factors of AMI in men and its influence on lipid profile in men is still controversial. The aim of the study was to determine levels of T in AMI and six months after AMI in the same group of patients, and to compare with T levels in healthy men. Also we correlated T levels with lipid profile in patients with AMI and 6 months after AMI. Methods. The study was designed as prospective study. Patients were divided into III groups: Group I included 35 men, aged 55 ± 3 years, with AMI. Group II included the same 35 patients, analyzed 6 months after AMI. The group III consisted of 20 healthy men aged 57 ± 2.12 years (control group). Blood samples of the group I (AMI) were taken in the first 12 hours from the AMI beginning and also 6 months after AMI (group II). Following analyses were performed: levels of total cholesterol, triglycerides, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, lipoprotein(a) [Lp(a)], apolipoprotein A1 (Apo A1), apolipoprotein B (Apo B) and T. Results. Levels of T in patients with AMI (16.86 ± 7.18 nmol/L) as well as 6 months after AMI (18.12 ± 7.96 nmol/L) were statistically significantly lower than those in healthy persons of the same age (27.11 ± 10.48 nmol/L) (p < 0.001). In the group I, statistically significant, positive correlation was found between levels of T and HDL cholesterol (r = 0.403, p < 0.05), and levels of T and Apo A1 (r = 0.747, p < 0.01). In the group II, statistically significant, positive correlation was also found between levels of T and HDL cholesterol (r = 0.388, p < 0.05) and T and Apo A1(r = 0.354, p < 0.05). Conclusion. This study showed that men, over 40 years of age, with AMI had statistically significantly lower concentrations of endogenous T compared to healthy male population of the same age. Levels of T in the same patients after 6 months from AMI maintained statistically significantly lower values in comparison to those in healthy men.

References

Von Eckardstein A. Androgens, cardiovascular risk factors, and atherosclerosis. In: Nieschlag E, Behre HM, editors. Testos-terone: Action, Deficiency, Substitution. 2nd ed. Berlin, Hei-delberg New: Springer; 1998. pp. 229–58.

Godsland IF. Cnages in metabolic inflammatory and endotheli-al indices of carsiovascularrisk. In: Lunenfeld B, Gooren L, edi-tors. Textbook of Men’s Health. New York, NY: Partenon Publishing Group; 2002. p. 317–8.

Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364(9438): 937–52.

Walldius G, Jungner I. Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid-lowering therapy. Eur Heart J 2005; 26(3): 210–2.

Godsland IF, Wynn V, Crook D, Miller NE. Sex, plasma lipo-proteins, and atherosclerosis: prevailing assumptions and out-standing questions. Am Heart J 1987; 114(6): 1467–503.

Dickerman RD, McConathy WJ, Zachariah NY. Testosterone, sex hormone-binding globulin, lipoproteins, and vascular disease risk. J Cardiovasc Risk 1997; 4(5–6): 363–6.

Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improve-ment in the prediction of fatal myocardial infarction (AMO-RIS study): a prospective study. Lancet 2001; 358(9298): 2026–33.

Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364(9438): 937–52.

Meisinger C, Loewel H, Mraz W, Koenig W. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial in-farction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur Heart J 2005; 26(3): 271–8.

Palabrica TM, Liu AC, Aronovitz MJ, Furie B, Lawn RM, Furie BC. Antifibrinolytic activity of apolipoprotein(a) in vivo: hu-man apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat Med 1995; 1(3): 256–9.

Zioncheck TF, Powell LM, Rice GC, Eaton DL, Lawn RM. Inter-action of recombinant apolipoprotein(a) and lipoprotein(a) with macrophages. J Clin Invest 1991; 87(3): 767–71.

von Eckardstein A, Schulte H, Cullen P, Assmann G. Lipopro-tein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 2001; 37(2): 434–9.

Muller M, van der Schouw YT, Thijssen JH, Grobbee DE. Endog-enous sex hormones and cardiovascular disease in men. J Clin Endocrinol Metab 2003; 88(11): 5076–86.

Christou GA, Christou KA, Nikas DN, Goudevenos JA. Acute myocardial infarction in a young bodybuilder taking anabolic androgenic steroids: A case report and critical review of the literature. Eur J Prev Cardiol 2016; 23(16): 1785–96.

Layton JB, Li D, Meier CR, Sharpless JL, Stürmer T, Brookhart MA. Injection testosterone and adverse cardiovascular events: A case-crossover analysis. Clin Endocrinol (Oxf) 2018; 88(5): 719–27.

Li H, Mitchell L, Zhang X, Heiselman D, Motsko S. Testosterone Therapy and Risk of Acute Myocardial Infarction in Hy-pogonadal Men: An Administrative Health Care Claims Study. J Sex Med 2017; 14(11): 1307–17.

Cheetham TC, An J, Jacobsen SJ, Niu F, Sidney S, Quesenberry CP, et al. Association of Testosterone Replacement With Cardio-vascular Outcomes Among Men With Androgen Deficiency. JAMA Intern Med 2017; 177(4): 491–9.

Fortunati N. Sex hormone-binding globulin: not only a transport protein. What news is around the corner? J Endo-crinol Invest 1999; 22(3): 223–34.

Duell PB, Bierman EL. The relationship between sex hormones and high-density lipoprotein cholesterol levels in healthy adult men. Arch Intern Med 1990; 150(11): 2317–20.

Page ST, Mohr BA, Link CL, O'Donnell AB, Bremner WJ, McKinlay JB. Higher testosterone levels are associated with in-creased high-density lipoprotein cholesterol in men with car-diovascular disease: results from the Massachusetts Male Aging Study. Asian J Androl 2008; 10(2): 193–200.

Haffner SM, Mykkänen L, Valdez RA, Katz MS. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab 1993; 77(6): 1610–5.

Agledahl I, Skjaerpe PA, Hansen JB, Svartberg J. Low serum tes-tosterone in men is inversely associated with non-fasting se-rum triglycerides: the Tromsø study. Nutr Metab Cardiovasc Dis 2008; 18(4): 256–62.

Hämäläinen E, Adlercreutz H, Ehnholm C, Puska P. Relation-ships of serum lipoproteins and apoproteins to sex hormones and to the binding capacity of sex hormone binding globulin in healthy Finnish men. Metabolism 1986; 35(6): 535–41.

Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990; 10(2): 240–5.

Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for li-pid-modifying therapy. J Intern Med 2004; 255(2): 188–205.

Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD, Sniderman AD. The apoB/apoA-I ratio is better than the cho-lesterol ratios to estimate the balance between plasma proath-erogenic and antiatherogenic lipoproteins and to predict coro-nary risk. Clin Chem Lab Med 2004; 42(12): 1355–63.

Wallenfeldt K, Bokemark L, Wikstrand J, Hulthe J, Fagerberg B. Apolipoprotein B/apolipoprotein A-I in relation to the meta-bolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke 2004; 35(10): 2248–52.

Liting P, Guoping L, Zhenyue C. Apolipoprotein B/apolipoprotein A1 ratio and non-high-density lipoprotein cholesterol. Predictive value for CHD severity and prognostic utility in CHD patients. Herz 2015; 40 Suppl 1: 1–7.

Oh JY, Barrett-Connor E, Wedick NM, Wingard DL. Rancho Bernardo Study. Endogenous sex hormones and the develop-ment of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 2002; 25(1): 55–60.

Livingstone C, Collison M. Sex steroids and insulin resistance. Clin Sci (Lond) 2002; 102(2): 151–66.

Seidell JC, Björntorp P, Sjöström L, Kvist H, Sannerstedt R. Vis-ceral fat accumulation in men is positively associated with in-sulin, glucose, and C-peptide levels, but negatively with tes-tosterone levels. Metabolism 1990; 39(9): 897–901.

Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Interven-tion Trial participants. Am J Epidemiol 1997; 146(8): 609–17.

Haffner SM. Androgens in relation to cardiovascular disease and insulin resistend in aging male. In: Oddens BJ, Vermeulen A, editors. Androgens and the aging male. New York: The Parthenon Publishing Group; 1996. p. 68–72.

Tikkanen MJ, Nikkilä EA, Kuusi T, Sipinen SU. High density lipoprotein-2 and hepatic lipase: reciprocal changes produced by estrogen and norgestrel. J Clin Endocrinol Metab 1982; 54(6): 1113–7.